DE2946275C2 - - Google Patents
Info
- Publication number
- DE2946275C2 DE2946275C2 DE2946275A DE2946275A DE2946275C2 DE 2946275 C2 DE2946275 C2 DE 2946275C2 DE 2946275 A DE2946275 A DE 2946275A DE 2946275 A DE2946275 A DE 2946275A DE 2946275 C2 DE2946275 C2 DE 2946275C2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- interferon
- human
- substance
- priming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000004027 cell Anatomy 0.000 claims description 60
- 102000014150 Interferons Human genes 0.000 claims description 32
- 108010050904 Interferons Proteins 0.000 claims description 32
- 229940079322 interferon Drugs 0.000 claims description 27
- 230000037452 priming Effects 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 230000016396 cytokine production Effects 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 5
- 229940047124 interferons Drugs 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 235000021391 short chain fatty acids Nutrition 0.000 claims description 3
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 description 10
- 241000711408 Murine respirovirus Species 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000012045 crude solution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000002799 interferon inducing agent Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792946275 DE2946275A1 (de) | 1979-11-16 | 1979-11-16 | Verbessertes verfahren zur herstellung von humaninterferon aus lymphoblastoiden zellen |
| AT0506880A AT374828B (de) | 1979-11-16 | 1980-10-13 | Verfahren zur herstellung von humaninterferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792946275 DE2946275A1 (de) | 1979-11-16 | 1979-11-16 | Verbessertes verfahren zur herstellung von humaninterferon aus lymphoblastoiden zellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2946275A1 DE2946275A1 (de) | 1981-05-27 |
| DE2946275C2 true DE2946275C2 (enrdf_load_stackoverflow) | 1987-11-05 |
Family
ID=6086143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792946275 Granted DE2946275A1 (de) | 1979-11-16 | 1979-11-16 | Verbessertes verfahren zur herstellung von humaninterferon aus lymphoblastoiden zellen |
Country Status (2)
| Country | Link |
|---|---|
| AT (1) | AT374828B (enrdf_load_stackoverflow) |
| DE (1) | DE2946275A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3016255A1 (de) * | 1980-04-26 | 1981-10-29 | Messerschmitt-Bölkow-Blohm GmbH, 8000 München | Gasgefuellter fahrzeugreifen |
| DE3930140A1 (de) * | 1989-09-09 | 1991-03-21 | Bayer Ag | Verfahren zur herstellung von biologischen materialien in zellkulturen und vorrichtungen |
| AU2020355194A1 (en) * | 2019-09-25 | 2022-04-28 | Julius-Maximilians-Universität Würzburg | Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS215108B2 (en) * | 1977-07-15 | 1982-07-30 | Wellcome Found | Method of making the interferrone |
-
1979
- 1979-11-16 DE DE19792946275 patent/DE2946275A1/de active Granted
-
1980
- 1980-10-13 AT AT0506880A patent/AT374828B/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATA506880A (de) | 1983-10-15 |
| AT374828B (de) | 1984-06-12 |
| DE2946275A1 (de) | 1981-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3853535T2 (de) | Ärztliche antimikrobielle polypeptide, deren verwendung und verfahren zur herstellung. | |
| DE3689246T2 (de) | Physiologisch aktives Polypeptid BUF-3. | |
| EP0005476B1 (de) | Verfahren zur Herstellung von Humaninterferon | |
| DE3704389C2 (enrdf_load_stackoverflow) | ||
| DE69329841T2 (de) | Verfahren zur Unterdrückung der Koloration von menschlichem Serum-Albumin | |
| DE2946275C2 (enrdf_load_stackoverflow) | ||
| CH628246A5 (de) | Verfahren zur herstellung eines schuetzenden pertussis-antigens. | |
| CH651317A5 (de) | Verfahren zur enzymatischen synthese von doppelstrangiger rna, nach diesem verfahren synthetisierte doppelstrangige rna und diese enthaltende interferon-induktoren. | |
| EP0062085B1 (de) | Verbessertes Verfahren zur Herstellung von Humaninterferon aus lymphoblastoiden Zellen | |
| DE3434122C2 (enrdf_load_stackoverflow) | ||
| EP0367840A1 (de) | Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie | |
| DE3325131C2 (enrdf_load_stackoverflow) | ||
| DE2821466A1 (de) | Verbessertes verfahren zur herstellung von humaninterferon | |
| DE69107815T2 (de) | Verfahren zur Herstellung neuer nichtkovalenten Polysaccharid-Protein-Zusammensetzungen mit pharmakologischen Eigenschaften. | |
| EP0203382A2 (de) | Verfahren zur Herstellung und Reinigung von alpha-Interferon | |
| CS251766B2 (en) | Method of interferon production | |
| EP0480389A1 (de) | Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung | |
| DE69710349T2 (de) | 1,3-dicarbonsäuregermaniumkomplex und dessen therapeutische verwendung | |
| DE3249215T1 (de) | Verfahren zur herstellung von humanem (gamma)-interferon | |
| DE2724918A1 (de) | Gewinnung und reinigung von humaninterferon | |
| DE3019621C2 (de) | Verfahren zur Herstellung von Interferon II. | |
| DE1115888B (de) | Verfahren zur Herstellung eines Streptokinase-Praeparates | |
| DE4133707A1 (de) | Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung | |
| DE2906160A1 (de) | Verbessertes verfahren zur herstellung von humaninterferon | |
| EP0135797A2 (de) | Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |